Angiotensin II inhibition and prevention of atrial fibrillation and stroke

J Am Coll Cardiol. 2005 Mar 1;45(5):720-1. doi: 10.1016/j.jacc.2004.12.008.
No abstract available

Publication types

  • Comment
  • Comparative Study
  • Editorial

MeSH terms

  • Adrenergic beta-Antagonists / therapeutic use
  • Aged
  • Angiotensin II Type 1 Receptor Blockers / therapeutic use*
  • Antihypertensive Agents / therapeutic use*
  • Atenolol / therapeutic use
  • Atrial Fibrillation / mortality
  • Atrial Fibrillation / prevention & control*
  • Cause of Death
  • Double-Blind Method
  • Electrocardiography / drug effects
  • Female
  • Humans
  • Hypertension / drug therapy*
  • Hypertension / mortality
  • Losartan / therapeutic use*
  • Male
  • Middle Aged
  • Myocardial Infarction / mortality
  • Myocardial Infarction / prevention & control
  • Prospective Studies
  • Randomized Controlled Trials as Topic
  • Stroke / mortality
  • Stroke / prevention & control*
  • Survival Rate

Substances

  • Adrenergic beta-Antagonists
  • Angiotensin II Type 1 Receptor Blockers
  • Antihypertensive Agents
  • Atenolol
  • Losartan